BioCentury | Mar 12, 2012
Finance

Argos plowing ahead

...to $9.5M. Cornerstone also announced it divested its anti-infective assets Factive gemifloxacin mesylate and Spectracef cefditoren pivoxil...
BioCentury | Nov 7, 2011
Finance

Clovis closes in

...zileuton were up 16% to $9.3M and 10% to $8.3M, respectively. Sales of antibiotic Spectracef cefditoren pivoxil...
BioCentury | Jul 20, 2009
Company News

Cornerstone Therapeutics, Oscient deal

...Italy) and Mexican rights to Pfizer Inc. (NYSE:PFE, New York, N.Y.). Cornerstone already markets Spectracef cefditoren pivoxil...
BioCentury | May 18, 2009
Finance

Ebb & Flow

...HyoMax line of products, which combine four generic antispasmodic medications to treat gastrointestinal disorders, and Spectracef...
BioCentury | May 12, 2008
Finance

Ebb & Flow

...will market Critical's asthma drugs Zyflo immediate-release zileuton and Zyflo CR tablets and Cornerstone's marketed Spectracef...
BioCentury | May 5, 2008
Company News

Cornerstone BioPharma Inc., Critical Therapeutics deal

...company will market Critical's asthma drugs Zyflo immediate-release zileuton and Zyflo CR tablets and Cornerstone's Spectracef...
BioCentury | Sep 17, 2001
Clinical News

Spectracef cefditoren pivoxil regulatory update

...The FDA granted marketing approval for Tap's Spectracef cephalosporin antibiotic to treat acute exacerbations of chronic...
...antibiotic to treat acute exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin infections. Tap licensed Spectracef...
...Seika Kaisha Ltd. (Tokyo, Japan). Tap Pharmaceutical Products Inc. , Lake Forest, Ill. Product: Spectracef cefditoren pivoxil...
BioCentury | Sep 12, 2001
Company News

FDA approves Tap's Spectracef

...The FDA granted marketing approval for Spectracef cefditoren pivoxil from Tap Pharmaceutical (Lake Forest, Ill.) to treat...
...Ill.) to treat acute exacerbations of chronic bronchitis, pharyngitis/tonsillitis and uncomplicated skin infections. Tap licensed Spectracef...
BioCentury | Sep 25, 2000
Clinical News

Spectracef cefditoren pivoxil: Phase III data; NDA under review

...TAP said the clinical cure rates for evaluable patients receiving 200 and 400 mg of Spectracef...
...from Meiji Seika Kaisha Ltd. (Tokyo, Japan). TAP Pharmaceuticals Inc., Lake Forest, Ill. Product: Spectracef cefditoren pivoxil...
BioCentury | Sep 18, 2000
Clinical News

TAP reports Phase III Spectracef data

...TAP Pharmaceuticals (Deerfield, Ill.) said that in a Phase III study of its Spectracef cefditoren pivoxil oral...
...equivalence between cefditoren and clarithromycin. In January, TAP submitted an NDA to the FDA for Spectracef...
Items per page:
1 - 10 of 11